المؤلفون: A. D. Makatsariya, K. N. Grigoreva, M. A. Mingalimov, V. O. Bitsadze, J. Kh. Khizroeva, M. V. Tretyakova, I. Elalamy, A. S. Shkoda, V. B. Nemirovskiy, D. V. Blinov, D. V. Mitryuk, А. Д. Макацария, К. Н. Григорьева, М. А. Мингалимов, В. О. Бицадзе, Д. Х. Хизроева, М. В. Третьякова, И. Элалами, А. С. Шкода, В. Б. Немировский, Д. В. Блинов, Д. В. Митрюк

المصدر: Obstetrics, Gynecology and Reproduction; Vol 14, No 2 (2020); 123-131 ; Акушерство, Гинекология и Репродукция; Vol 14, No 2 (2020); 123-131 ; 2500-3194 ; 2313-7347

مصطلحات موضوعية: НМГ, COVID-19, coronavirus, disseminated intravascular coagulation, DIC, anticoagulant therapy, low molecular weight heparin, LMWH, коронавирус, синдром диссеминированного внутрисосудистого свертывания, ДВС-синдром, антикоагулянтная терапия, низкомолекулярный гепарин

وصف الملف: application/pdf

Relation: https://www.gynecology.su/jour/article/view/633/798; https://www.gynecology.su/jour/article/view/633/799; Novel Coronavirus – China. World Health Organization. January 12, 2020. Available at: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en. [Accessed: 08.04.2020].; Zhu N., Zhang D., Wang W. et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. DOI:10.1056/NEJMoa2001017.; Li Q., Guan X., Wu P. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207. DOI:10.1056/NEJMoa2001316.; Chan J. F., Yuan S., Kok K.H. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster. Lancet. 2020;395(10223):514–52. DOI:10.1016/S0140-6736(20)30154-9.; Levi M., van der Poll T. A short contemporary history of disseminated intravascular coagulation. Semin Thromb Hemost. 2014;40(8):874– 80. DOI:10.1055/s-0034-1395155.; Boral B., Williams D., Boral L. Disseminated intravascular coagulation. Am J Clin Pathol. 2016;146(6):670–80. DOI:10.1093/ajcp/aqw195.; Vaught A. J. Critical care for the obstetrician and gynecologist: obstetric hemorrhage and disseminated intravascular coagulopathy. Obstet Gynecol Clin North Am. 2016;43(4):611–22. DOI:10.1016/j.ogc.2016.07.006.; Levi M. Pathogenesis and diagnosis of disseminated intravascular coagulation. Int J Lab Hematol. 2018;40(Suppl 1):15–20. DOI:10.1111/ijlh.12830.; Moellering R.C., Abbott G. F., Ferraro M. J. Case records of the Massachussets General Hospital. Case 2–2011. A 30-year-old woman with shock after treatment for a furuncle. N Engl J Med. 2011;364(3):266–75. DOI:10.1056/NEJMcpc1003886.; Russell J.A. Management of sepsis. N Engl J Med. 2006;355(16):1699–713. DOI:10.1056/NEJMra043632.; Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI:10.1016/S0140-6736(20)30183-5.; Guan W.J., Ni Z.Y., Hu Y. et al; China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Feb 28. DOI:10.1056/NEJMoa2002032. [Epub ahead of print].; Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7. DOI:10.1111/jth.14768.; Brun-Buisson C., Doyon F., Carlet J. et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 1995;274(12):968–74.; Vanderschueren S., De Weerdt A., Malbrain M. et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28(6):1871–6. DOI:10.1097/00003246-200006000-00031.; Lippi G., Plebani M., Henry B.M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020;506:145–8. DOI:10.1016/j.cca.2020.03.022.; Wada H., Thachil J., Di Nisio M. et al; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11:761–7. DOI:10.1111/jth.12155.; Taylor F. B., Toh C.H., Hoots W. K. et al; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–30.; Levi M., Toh C.H., Thachil J., Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145(1):24–33. DOI:10.1111/j.1365-2141.2009.07600.x.; Di Nisio M., Baudo F., Cosmi B. et al; Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2012;129(5):e177–84. DOI:10.1016/j.thromres.2011.08.028.; Gando S., Levi M., Toh C.H. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016;2(1):16037. DOI:10.1038/nrdp.2016.38.; Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care. 2014;2(1):67. DOI:10.1186/s40560-014-0065-0.; Tang N., Bai H., Chen X. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. Mar 27. DOI:10.1111/jth.14817. [Epub ahead of print].; Iba T., Nisio M.D., Levy J.H. et al. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046. DOI:10.1136/bmjopen-2017-017046.; Poterucha T. J., Libby P., Goldhaber S.Z. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb Haemost. 2017;117(3):437–44. DOI:10.1160/TH16-08-0620.; https://www.gynecology.su/jour/article/view/633

الاتاحة: https://www.gynecology.su/jour/article/view/633
https://doi.org/10.17749/2313-7347.132

المؤلفون: A. D. Makatsariya, G. C. Di Renzo, G. Rizzo, V. O. Bitsadze, J. Kh. Khizroeva, D. V. Blinov, E. I. Vovk, I. E. Govorov, D. L. Guryev, G. B. Dikke, M. S. Zainulina, N. S. Zakharova, V. V. Kovalev, E. V. Komlichenko, V. A. Kramarskiy, A. B. Loginov, L. I. Maltseva, V. B. Nemirovskiy, D. A. Ponomarev, E. B. Rudakova, N. V. Samburova, O. F. Serova, F. K. Tetelyutina, M. V. Tretyakova, J. Yu. Ungiadze, V. I. Tsibizova, А Д. Макацария, Д. К. Ди Ренцо, Д. Риццо, В. О. Бицадзе, Д. Х. Хизроева, Д. В. Блинов, Е. И. Вовк, И. Е. Говоров, Д. Л. Гурьев, Г. Б. Дикке, М. С. Зайнулина, Н. С. Захарова, В. В. Ковалев, Э. В. Комличенко, В. А. Крамарский, А. Б. Логинов, Л. И. Мальцева, В. Б. Немировский, Д. А. Пономарев, Е. Б. Рудакова, Н. В. Самбурова, О. Ф. Серова, Ф. К. Тетелютина, М. В. Третьякова, Д. Ю. Унгиадзе, В. И. Цибизова

المصدر: Obstetrics, Gynecology and Reproduction; Vol 14, No 3 (2020); 374-383 ; Акушерство, Гинекология и Репродукция; Vol 14, No 3 (2020); 374-383 ; 2500-3194 ; 2313-7347

مصطلحات موضوعية: доказательная база, progesterone, didrogesterone, habitual miscarriage, evidence base, прогестерон, дидрогестерон, невынашивание беременности

وصف الملف: application/pdf

Relation: https://www.gynecology.su/jour/article/view/783/825; Акушерство: национальное руководство. Под ред. Г. М. Савельевой, Г. Т. Сухих, В. Н. Серова, В. Е. Радзинского. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2018. 1088 с.; Макацария А. Д., Бицадзе В. О., Хизроева Д. Х. и др. Новая коронавирусная инфекция (COVID-19) и группы риска в акушерстве и гинекологии. Акушерство, Гинекология и Репродукция. 2020;14(2):159–62. https://doi.org/10.17749/2313-7347.133.; Макацария А. Д., Григорьева К. Н., Мингалимов М. А. и др. К оронавирусная инфекция (COVID-19) и синдром диссеминированного внутрисосудистого свертывания. Акушерство, Гинекология и Репродукция. 2020;14(2):123–31. https://doi.org/10.17749/2313-7347.132.; Coomarasamy A., Helen Williams H., Truchanowicz E. et al. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med. 2015;373(22):2141–8. https://doi.org/10.1056/NEJMoa1504927.; Манухин И. Б., Добрoхотова Э. Ю., Кулещов В. М. и др. Лечение угрожающего выкидыша препаратами микронизированного прогестерона и дидрогестерона (результаты многоцентрового открытого проспективного сравнительного неинтервенционного исследования). Проблемы репродукции. 2018;24(3):34–42. https://doi.org/10.17116/repro201824334.; Coomarasamy A., Devall A. J., Cheed V. et al. A randomized trial of progesterone in women with bleeding in early pregnancy. N Engl J Med. 2019;380(19):1815–24. https://doi.org/10.1056/NEJMoa1813730.; Распоряжение Правительства РФ от 12 октября 2019 г. № 2406-р. M., 2019. 261 c.; Письмо Минздрава России от 13 февраля 2020 г. N 15-4/И/368-07 О направлении клинических рекомендаций «Нормальная беременность». M., 2020. 89 c.; Письмо Минздрава России от 17.12.2013 г. N 15-4/10/2-9480 – О направлении клинических рекомендаций «Преждевременные роды». М., 2013. 35 с.; Письмо Минздрава России от 15.02.2019 г. N 15-4/И/2-1218 – О направлении клинических рекомендаций (протокола лечения) «Женское бесплодие (современные подходы к диагностике и лечению)». M., 2019. 100 c.; Письмо Минздрава России от 28 декабря 2018 г. N 15-4/10/2-7991 О клинических рекомендациях (протоколе лечения) «Истмико-цервикальная недостаточность». М., 2018. 29 с.; Письмо Минздрава России от 7 июня 2016 г. N 15-4/10/2-3482 – О направлении клинических рекомендаций (протокола лечения) «Выкидыш в ранние сроки беременности: диагностика и тактика ведения». М., 2016. 19 с.; Coomarasamy A., Devall A. J., Brosens J. J. et al. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am J Obstet Gynecol. 2020;223(2):167–76. https://doi.org/10.1016/j.ajog.2019.12.006.; Заключение Экспертного Совета по итогам 2-го Всемирного конгресса медицины матери, плода и новорожденного «Микронизированный прогестерон в лечении невынашивания». Проблемы репродукции. 2019;25(2):46–50. https://doi.org/10.17116/repro20192502146.; Siew J. Y.S., Allen J. C., Hui C. Y.Y. et al. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet Gynecol Reprod Biol. 2018;228:319–24. https://doi.org/10.1016/j.ejogrb.2018.07.028.; Czajkowski K., Sienko J., Mogilinski M. et al. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril. 2007;87(3):613–8. https://doi.org/10.1016/j.fertnstert.2006.07.1506.; Da Fonseka E. B., Bittar R. E., Carvalho M. H.B., Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188(2):419–24. https://doi.org/10.1067/mob.2003.41.; Romero R., Conde-Agudelo A., Da Fonseca E. et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. Am J Obstet Gynecol. 2018;218(2):161–80. https://doi.org/10.1016/j.ajog.2017.11.576.; Dodd J. M., Jones L., Flenady V. et al. Prenatal administration of progesterone for preventing pretermbirth in women considered to be at risk of preterm bir th. Cochrane Database Syst Rev. 2013;31(7):CD004947. https://doi.org/10.1002/14651858.CD004947.pub3.; Jarde A., Lutsiv O., Park C. K. et al. Effectiveness of progesterone, cerclage and pessary for preventing preterm birth in singleton pregnancies: a systematic review and network meta-analysis. BJOG. 2017;124(8):1176–89. https://doi.org/10.1111/1471-0528.14624.; Romero R., Conde-Agudelo A., El-Refaie W. et al. Vaginal progesterone decreases preterm bir th and neonatal morbidity and mortality in women with a twin gestation and a shor t cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol. 2017;49(3):303–14. https://doi.org/10.1002/uog.17397.; Farine D., Mundle W., Dodd J. The use of progesterone for prevention of preterm birth. J Obstet Gynaecol Can. 2008;30(1):67–71. https://doi.org/10.1016/S1701-2163(16)32716-5.; SMFM clinical guidelines. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol. 2012;206(5):376–86. https://doi.org/10.1016/j.ajog.2012.03.010.; FIGO Working Group on Best Practice in Maternal – Fetal Medicine. Best practice in maternal–fetal medicine. Int J Gynecol Obstet. 2015;128(1):80–2. https://doi.org/10.1016/j.ijgo.2014.10.011.; Di Renzo G. C., Cabero Roura L., Facchinetti F. et al. Preterm labor and birth management: recommendations from the European Association of Perinatal Medicine. J Matern Fetal Neonatal Med. 2017;30(17):2011–30. https://doi.org/10.1080/14767058.2017.1323860.; Hassan S., Romero R., Vidyadhari D. et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38(1):18–31. https://doi.org/10.1002/uog.901.; McNamara H.C., Wood R., Chalmers J. et al. (2015) STOPPIT Baby Follow-Up Study: The effect of prophylactic progesterone in twin pregnancy on childhood outcome. PLoS One. 2015;10(4):e0122341. https://doi.org/10.1371/journal.pone.0122341.; Coomarasamy A., Williams H., Truchanowicz E. et al. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med. 2015;373(22):2141–8. https://doi.org/10.1056/NEJMoa1504927.; Norman J. E., Marlow N., Messow C-M. et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016;387(10033):2106–6. https://doi.org/10.1016/S0140-6736(16)00350-0.; Ovarian stimulation for IVF/ICSI. Guideline of the European Society of Human Reproduction and Embryology. ESHRE Reproductive Endocrinology Guideline Group, 2019. 136 p. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Ovarian-Stimulation-in-IVF-ICSI. [Accessed: 16.07.2020].; Romero R., Stanczyk F. Z. Progesterone is not the same as 17-hydroxyprogesterone caproate: implications for obstetrical practice. Am J Obstet Gynecol. 2013;208(6):421–6. https://doi.org/10.1016/j.ajog.2013.04.027.; Romero R., Yeo L., Miranda J. et al. A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. J Perinat Med. 2013;41(1):27–44. https://doi.org/10.1515/jpm-2012-0272.; Meis P. J., Klebanoff M., Thom E. et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379–85. https://doi.org/10.1056/NEJMoa035140.; Zaqout M., Aslem E., Abuqamar M. et al. The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy. Pediatr Cardiol. 2015;36(7):1483–8. https://doi.org/10.1007/s00246-015-1190-9.; Zaqout M., Aslem E., Abuqamar M. et al. Association between oral intake of dydrogesterone during early pregnancy and congenital heart disease: a case-control study. Lancet. 2017;390:S8. https://doi.org/10.1016/s0140-6736(17)32059-7.; Koren G. Dydrogesterone exposure in the first trimester of pregnancy and fetal malformations. Motherisk Int J. 2020;1:11.; https://www.gynecology.su/jour/article/view/783

الاتاحة: https://www.gynecology.su/jour/article/view/783
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2020.171